This study is looking at an experimental drug called odronextamab combined with lenalidomide. It is for adults with follicular lymphoma or marginal zone lymphoma that has come back after treatment or did not respond to treatment. The goal is to see if this combination works better and is safe compared to the current standard treatment, rituximab with lenalidomide. The study has two parts: the first part checks safety and the second part compares the effectiveness of the treatments.
The trial's ID number is NCT06149286. It is a Phase 3 study, which means it is looking at how well the treatment works and how safe it is. The trial is regulated by the FDA and aims to enroll about 470 participants.
Who can join
This study is open to adults aged 18 and older, including both men and women. Participants must have certain types of lymphoma and have had prior treatment that did not work or has come back. There are some health conditions and other factors that may prevent someone from joining. The trial team will confirm if someone is eligible to participate.
Conditions
Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will be placed into one of two groups. In the first part, everyone will receive odronextamab with lenalidomide. In the second part, participants will be randomly assigned to either receive odronextamab with lenalidomide or rituximab with lenalidomide. All participants will receive the drugs as outlined in the study plan.
Where
This trial is enrolling at 8 locations. Recruiting sites are listed first.
Boca Raton Clinical Research (BRCR) Global
Plantation, Florida
Recruiting
Dartmouth Cancer Center
Lebanon, New Hampshire
Recruiting
David Geffen School of Medicine at UCLA
Los Angeles, California
Recruiting
Hattiesburg Clinic
Hattiesburg, Mississippi
Recruiting
Indiana University and Comprehensive Cancer Center
Professor and transplant specialist, UC Davis. Treats leukemia, lymphoma and multiple myeloma. The main doctor for adults with blood cancers, like leukemia, lymphoma, and myeloma. Recognized at state, national or international level.
Associate Professor of Radiation Oncology at the University of Vermont Larner College of Medicine and practices. Treats lung cancer, breast cancer, anal cancer and bone cancer. Also treats brain tumor, lymphoma and pancreatic cancer.